Max Sung

Author PubWeight™ 12.09^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.	Cancer Res	2009	3.18
2	Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters.	Ann Surg	2002	2.14
3	Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.	Lancet Oncol	2002	1.52
4	Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis.	Cancer Res	2003	1.20
5	Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.	Oncologist	2005	0.96
6	Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.	Cancer Chemother Pharmacol	2010	0.83
7	A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.	Am J Clin Oncol	2011	0.78
8	Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.	Am J Cancer Res	2013	0.76
9	Clinical pathways for pancreatic neuroendocrine tumors.	J Gastrointest Cancer	2012	0.76